A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.

Publication Type:

Journal Article

Authors:

Chiorean, E Gabriela; Sweeney, Christopher; Youssoufian, Hagop; Qin, Amy; Dontabhaktuni, Aruna; Loizos, Nick; Nippgen, Johannes; Amato, Robert

Source:

Cancer chemotherapy and pharmacology (2014)

Keywords:

2014, Clinical Research Division, February 2014

Abstract:

The platelet-derived growth factor receptor (PDGFR) has an important role in tumorigenesis and tumor progression. Olaratumab (IMC-3G3) is a fully human monoclonal antibody that selectively binds human PDGFRα and blocks ligand binding. This phase I study assessed the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), pharmacokinetics, and preliminary antitumor activity of olaratumab in patients with advanced solid tumors.